[practice logo]

|  |  |
| --- | --- |
|  | [practice address] |
|  | [practice address] |
|  | [practice address] |
|  | [practice address] |
|  |  |
|  |  |
|  | Tel: [practice telephone] |
|  | [Practice website] |
|  |  |

[date]

Dear [patient’s name]

Within the practice we regularly review our patients’ treatment to ensure local and national guidelines are being followed and that all treatment complies with current best practice.

Guidance has recently changed in Dorset and nationally regarding the first-choice anticoagulant (blood thinner). There are a number of medications available in this class, doctors have been advised that a medication called **edoxaban** is now the first-choice medication for all patients. All practices are being encouraged to review their prescribing of oral anticoagulants for patients with atrial fibrillation.

Research shows that edoxaban is safe and effective at reducing the risk of stroke in people with atrial fibrillation and is now available at a lower cost to the NHS. In the current financial climate, it would seem inappropriate to be prescribing more expensive products if they have no clinical benefit for you as the patient.

We would therefore like to invite you for a review of your blood thinner so we can discuss which medication is right for you, considering this new guidance.

Please contact our reception team to arrange a face to face, or telephone consultation with your GP/our practice pharmacist/our PCN pharmacist. **(delete as appropriate)**

Yours sincerely,

[name of GP]

[name of practice]